Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Fennec Q2 2026 shows PEDMARK momentum and EBITDA turning positive for FRX

Aug 11, 2026, 7:05 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong Q2 performance, positive EBITDA, cash runway, and ASCO data create near-term upside; cross-listing FRX on TSX could attract new buyers. However, higher S&M and promotional activity may temper near-term gains.

AI summary

What happened, with direct paths to the underlying reporting

Fennec reports Q2 2026 revenue growth with $17.1M PEDMARK net product sales, up 78% YoY, and non-GAAP EBITDA of $2.8M, aided by expanded commercial operations. ASCO data reinforced PEDMARK's clinical utility across pediatric, AYAs, and adult populations without reducing cisplatin activity. Management signaled continued demand and cash runway to fund growth.

Q2 2026 PEDMARK sales $17.1M, up 78% YoY; Non-GAAP EBITDA $2.8M.
Expanded commercial team drove PEDMARK demand; first full quarter post-expansion.
ASCO 2026 data support PEDMARK across populations; no cisplatin activity compromise.
Cash $41.2M at 6/30/2026; runway funds current plan.
Q2 call today 8:30am ET; H.C. Wainwright conference Sept 14–17.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.